Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IFRX
IFRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IFRX News
InflaRx to Participate in Investor Conferences
Jan 29 2026
Newsfilter
InflaRx Cuts 30% Workforce to Focus on Izicopan Development
Jan 08 2026
Benzinga
InflaRx Revives Vilobelimab Development with Positive Phase 3 Data, FDA Talks Ahead
Jan 05 2026
Benzinga
ARS Pharma's Neffy Approved in China for Allergy Treatment
Jan 02 2026
NASDAQ.COM
InflaRx Terminates Phase 3 Trial of Vilobelimab, Reveals Potential Efficacy Signals
Dec 30 2025
NASDAQ.COM
InflaRx Reports 20.8% Efficacy Improvement for Vilobelimab in Pyoderma Gangrenosum Study
Dec 30 2025
NASDAQ.COM
Most Active Stocks in Pre-Market Trading on November 10, 2025: IFRX, GREE, IPHA, TSLL, SQQQ, NVDA, PFE, BBAI, OSCR, IONQ, HLN, THS
Nov 10 2025
NASDAQ.COM
Viasat Shares Rise Approximately 13%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 10 2025
Benzinga
Biotech Update: IFRX, ABCL, RLYB Stand Out as Significant Gainers After Hours
Nov 10 2025
NASDAQ.COM
Analyst Sees Long-Term Promise in Biogen's Immunology Pipeline
Oct 24 2025
Benzinga
InflaRx to Take Part in Guggenheim Securities' 2nd Annual Healthcare Innovation Conference
Oct 21 2025
Newsfilter
"Four Biotech Stocks Poised for Breakout as Momentum Scores Rise"
Sep 08 2025
Benzinga
HC Wainwright & Co. Initiates Coverage on InflaRx with a Buy Rating and Sets Price Target at $6
Sep 02 2025
Benzinga
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
Jul 31 2025
Newsfilter
Oppenheimer Maintains Outperform on InflaRx, Lowers Price Target to $3
May 29 2025
Benzinga
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
May 28 2025
TipRanks
Show More News
